243 related articles for article (PubMed ID: 33767344)
1. Variant curation expert panel recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility.
Johnston JJ; Dirksen RT; Girard T; Gonsalves SG; Hopkins PM; Riazi S; Saddic LA; Sambuughin N; Saxena R; Stowell K; Weber J; Rosenberg H; Biesecker LG
Genet Med; 2021 Jul; 23(7):1288-1295. PubMed ID: 33767344
[TBL] [Abstract][Full Text] [Related]
2. Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility.
Johnston JJ; Dirksen RT; Girard T; Hopkins PM; Kraeva N; Ognoon M; Radenbaugh KB; Riazi S; Robinson RL; Saddic Iii LA; Sambuughin N; Saxena R; Shepherd S; Stowell K; Weber J; Yoo S; Rosenberg H; Biesecker LG
Hum Mol Genet; 2022 Nov; 31(23):4087-4093. PubMed ID: 35849058
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the impact of in silico predictors on clinical variant classification.
Wilcox EH; Sarmady M; Wulf B; Wright MW; Rehm HL; Biesecker LG; Abou Tayoun AN
Genet Med; 2022 Apr; 24(4):924-930. PubMed ID: 34955381
[TBL] [Abstract][Full Text] [Related]
4. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.
Ibarra Moreno CA; Kraeva N; Zvaritch E; Figueroa L; Rios E; Biesecker L; Van Petegem F; Hopkins PM; Riazi S
Br J Anaesth; 2020 Dec; 125(6):995-1001. PubMed ID: 32861507
[TBL] [Abstract][Full Text] [Related]
5. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Pejaver V; Byrne AB; Feng BJ; Pagel KA; Mooney SD; Karchin R; O'Donnell-Luria A; Harrison SM; Tavtigian SV; Greenblatt MS; Biesecker LG; Radivojac P; Brenner SE;
Am J Hum Genet; 2022 Dec; 109(12):2163-2177. PubMed ID: 36413997
[TBL] [Abstract][Full Text] [Related]
6. Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert Panel.
Goldstein JL; McGlaughon J; Kanavy D; Goomber S; Pan Y; Deml B; Donti T; Kearns L; Seifert BA; Schachter M; Son RG; Thaxton C; Udani R; Bali D; Baudet H; Caggana M; Hung C; Kyriakopoulou L; Rosenblum L; Steiner R; Pinto E Vairo F; Wang Y; Watson M; Fernandez R; Weaver M; Clarke L; Rehder C
Mol Genet Metab; 2023; 140(1-2):107715. PubMed ID: 37907381
[TBL] [Abstract][Full Text] [Related]
7. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework.
Tavtigian SV; Greenblatt MS; Harrison SM; Nussbaum RL; Prabhu SA; Boucher KM; Biesecker LG;
Genet Med; 2018 Sep; 20(9):1054-1060. PubMed ID: 29300386
[TBL] [Abstract][Full Text] [Related]
8. Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of
Sadhasivam S; Brandom BW; Henker RA; McAuliffe JJ
Pharmacogenomics; 2019 Sep; 20(14):989-1003. PubMed ID: 31559918
[No Abstract] [Full Text] [Related]
9. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup.
Walker LC; Hoya M; Wiggins GAR; Lindy A; Vincent LM; Parsons MT; Canson DM; Bis-Brewer D; Cass A; Tchourbanov A; Zimmermann H; Byrne AB; Pesaran T; Karam R; Harrison SM; Spurdle AB;
Am J Hum Genet; 2023 Jul; 110(7):1046-1067. PubMed ID: 37352859
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia.
White R; Schiemann AH; Burling SM; Bjorksten A; Bulger T; Gillies R; Hopkins PM; Kamsteeg EJ; Machon RG; Massey S; Miller D; Perry M; Snoeck MMJ; Stephens J; Street N; van den Bersselaar LR; Stowell KM
Br J Anaesth; 2022 Dec; 129(6):879-888. PubMed ID: 36208971
[TBL] [Abstract][Full Text] [Related]
11. Adapting the ACMG/AMP variant classification framework: A perspective from the ClinGen Hemoglobinopathy Variant Curation Expert Panel.
Kountouris P; Stephanou C; Lederer CW; Traeger-Synodinos J; Bento C; Harteveld CL; Fylaktou E; Koopmann TT; Halim-Fikri H; Michailidou K; Nfonsam LE; Waye JS; Zilfalil BA; Kleanthous M;
Hum Mutat; 2022 Aug; 43(8):1089-1096. PubMed ID: 34510646
[TBL] [Abstract][Full Text] [Related]
12. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
Luo X; Feurstein S; Mohan S; Porter CC; Jackson SA; Keel S; Chicka M; Brown AL; Kesserwan C; Agarwal A; Luo M; Li Z; Ross JE; Baliakas P; Pineda-Alvarez D; DiNardo CD; Bertuch AA; Mehta N; Vulliamy T; Wang Y; Nichols KE; Malcovati L; Walsh MF; Rawlings LH; McWeeney SK; Soulier J; Raimbault A; Routbort MJ; Zhang L; Ryan G; Speck NA; Plon SE; Wu D; Godley LA
Blood Adv; 2019 Oct; 3(20):2962-2979. PubMed ID: 31648317
[TBL] [Abstract][Full Text] [Related]
13. Specifications of the ACMG/AMP Variant Classification Guidelines for Germline
Hatton JN; Frone MN; Cox HC; Crowley SB; Hiraki S; Yokoyama NN; Abul-Husn NS; Amatruda JF; Anderson MJ; Bofill-De Ros X; Carr AG; Chao EC; Chen KS; Gu S; Higgs C; Machado J; Ritter D; Schultz KA; Soper ER; Wu MK; Mester JL; Kim J; Foulkes WD; Witkowski L; Stewart DR
Hum Mutat; 2023; 2023():. PubMed ID: 38084291
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss.
Patel MJ; DiStefano MT; Oza AM; Hughes MY; Wilcox EH; Hemphill SE; Cushman BJ; Grant AR; Siegert RK; Shen J; Chapin A; Boczek NJ; Schimmenti LA; Nara K; Kenna M; Azaiez H; Booth KT; Avraham KB; Kremer H; Griffith AJ; Rehm HL; Amr SS; Tayoun ANA;
Genet Med; 2021 Nov; 23(11):2208-2212. PubMed ID: 34230634
[TBL] [Abstract][Full Text] [Related]
15. VIP-HL: Semi-automated ACMG/AMP variant interpretation platform for genetic hearing loss.
Peng J; Xiang J; Jin X; Meng J; Song N; Chen L; Abou Tayoun A; Peng Z
Hum Mutat; 2021 Dec; 42(12):1567-1575. PubMed ID: 34428318
[TBL] [Abstract][Full Text] [Related]
16. Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel.
Burdon KP; Graham P; Hadler J; Hulleman JD; Pasutto F; Boese EA; Craig JE; Fingert JH; Hewitt AW; Siggs OM; Whisenhunt K; Young TL; Mackey DA; Dubowsky A; Souzeau E
Hum Mutat; 2022 Dec; 43(12):2170-2186. PubMed ID: 36217948
[TBL] [Abstract][Full Text] [Related]
17. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
Lee K; Krempely K; Roberts ME; Anderson MJ; Carneiro F; Chao E; Dixon K; Figueiredo J; Ghosh R; Huntsman D; Kaurah P; Kesserwan C; Landrith T; Li S; Mensenkamp AR; Oliveira C; Pardo C; Pesaran T; Richardson M; Slavin TP; Spurdle AB; Trapp M; Witkowski L; Yi CS; Zhang L; Plon SE; Schrader KA; Karam R
Hum Mutat; 2018 Nov; 39(11):1553-1568. PubMed ID: 30311375
[TBL] [Abstract][Full Text] [Related]
18. Gene-specific ACMG/AMP classification criteria for germline APC variants: Recommendations from the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel.
Spier I; Yin X; Richardson M; Pineda M; Laner A; Ritter D; Boyle J; Mur P; Hansen TVO; Shi X; Mahmood K; Plazzer JP; Ognedal E; Nordling M; Farrington SM; Yamamoto G; Baert-Desurmont S; Martins A; Borras E; Tops C; Webb E; Beshay V; Genuardi M; Pesaran T; Capellá G; Tavtigian SV; Latchford A; Frayling IM; Plon SE; Greenblatt M; Macrae FA; Aretz S;
Genet Med; 2024 Feb; 26(2):100992. PubMed ID: 37800450
[TBL] [Abstract][Full Text] [Related]
19. Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.
Ross JE; Zhang BM; Lee K; Mohan S; Branchford BR; Bray P; Dugan SN; Freson K; Heller PG; Kahr WHA; Lambert MP; Luchtman-Jones L; Luo M; Perez Botero J; Rondina MT; Ryan G; Westbury S; Bergmeier W; Di Paola J
Blood Adv; 2021 Jan; 5(2):414-431. PubMed ID: 33496739
[TBL] [Abstract][Full Text] [Related]
20. [The updates of the ACMG variant interpretation guidelines affect the pathogenicity determination of
Wu KL; Li J; Wang HY; Wang QJ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 May; 59(5):455-463. PubMed ID: 38811176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
